Article Text

Download PDFPDF

Fluoxetine decreased depressive symptoms in children and adolescents with non-psychotic major depressive disorder

Statistics from

OpenUrlCrossRefPubMedWeb of Science


To evaluate the efficacy and safety of fluoxetine in treating children and adolescents who have non-psychotic major depressive disorder (MDD).


Randomised, double blind, placebo controlled trial with 8 weeks of follow up.


Outpatient mood disorders programme in Dallas, USA.


96 patients (mean age 12 y, 54% boys) who met the Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, revised criteria for MDD. Exclusion criteria were bipolar disorder; psychotic depression; independent sleep wake disorder; substance abuse; anorexia nervosa; bulimia; previous treatment with fluoxetine, 20 mg/day, for ≥3 weeks; or a first degree relative with bipolar I disorder.


48 patients received fluoxetine, 20 mg/day, and 48 patients received a …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.